Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Ranging Study of Piromelatine in Patients With Mild Dementia Due to Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 16 Mar 2017
At a glance
- Drugs Piromelatine (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- Acronyms ReCOGNITION
- Sponsors NEURIM Pharmaceuticals
- 28 Sep 2016 According to Neurim media release, first patients have been enrolled in this study.
- 28 Jun 2016 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
- 28 Jun 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.